Standby Equity Distribution Agreement (Seda)

The SEDA agreement is the first step in the implementation of the terminology sheet, as already described in the ad hoc communication published on 14 February 2018. Elanix would therefore have access to 11 million euros (including SEDA) over the next three years as part of a financing mechanism to finance continued growth. A second agreement on the continuation of funding beyond SEDA has yet to be negotiated. As things stand, the second agreement will deal with convertible debt, with a higher total issue volume of up to EUR 10.0 million, which will be subject to approval at the next general meeting. Disclaimer This publication may not be published, disseminated or transmitted directly or indirectly to the United States of America (including its territories and property), Canada, Japan or Australia, or any other jurisdiction in which such notification may be unlawful. The dissemination of this advertising may be limited by law in certain legal systems and persons in possession of this document or other information to which it is referred should be aware of these restrictions and comply with them. Failure to comply with these restrictions may constitute a violation of the securities laws of such a jurisdiction. Evolva will create a first block of 25 million equity shares from authorized capital, which can be used for future share issues under the SEDA agreement or other financing purposes. At the current share price (CHF 0.59), the total commitment is approximately 51 million shares. At the time of publication, the number of Evolva shares issued was 399.2 million. NEW HAVEN, Conn., Jul 6, 2009 (GlobeNewswire via COMTEX News Network) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leading company in the discovery and development of small molecular drugs to fight the most difficult infectious diseases, announced today that it is a standby sale agreement (“SEDA”) with YA Global Master SPV, Ltd., a fund managed by Yorkville Advisors ,, at its sole discretion, to sell up to $15 million of common shares to YA.

Yorkville adapts its financing to the needs of each business and offers a mix of debt structures, bridge financings, asset-backed loans, capital facilities and, in some cases, capital inflows. Dr. Michael J. Nowak, Director of Healthcare Group and Managing Director of Yorkville, led YA`s commitment to Achillion. Dr Nowak said: “We offer innovative financing instruments for publicly traded companies. With the Achillion pipeline on exciting HCV links and the milestones these links can reach during the duration of the agreement, we are particularly pleased to be able to work with Achillion. Founded in January 2001 by Mark Angelo, Yorkville specializes in flexible and innovative investment and equity investments and financings in publicly traded companies in a variety of sectors such as energy, mining, media and telecommunications technologies (TMT), health and shipping. REINACH, Switzerland— (BUSINESS WIRE)-Evolva (SIX: EVE) announces the conclusion of a standby equitation distribution agreement (“SEDA”) with a fund managed by Yorkville Advisors Global, LLC (“Yorkville”).